ArticleFrontiers in nutrition2025
Serum creatinine-to-cystatin C ratio and 1-year mortality risk in advanced breast cancer patients: a multicenter retrospective cohort study.
Article in Frontiers in nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Creatinine-Cystatin C Discrepancy and Renal Transporter Polymorphisms in Japanese Patients with Breast Cancer Receiving Abemaciclib.Clinical pharmacology and therapeutics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Muscle wasting and sarcopenia in advanced breast cancer correlates with poor outcomes. The serum creatinine-to-cystatin C ratio (CCR) is a potential muscle mass biomarker, but its prognostic value in advanced breast cancer is unclear. Methods: This multicenter retrospective cohort study included 465 patients with stage III-IV breast cancer (2018-2023) receiving standard treatment. The creatinine-cystatin C ratio (CCR) was calculated based on baseline serum markers. The primary endpoint was the 1-year all-cause mortality rate, as assessed through medical records and follow-up. A multivariate Cox regression model was used to analyze the relationship between CCR and mortality, along with restricted cubic spline, Kaplan-Meier survival analysis, ROC curve, and subgroup analysis. Results: This study enrolled a total of 465 patients with stage III-IV breast cancer, with a median age of 52.0 (interquartile range [IQR], 47.0-60.0)years and a median creatinine-cystatin C ratio (CCR) of 1.0 (IQR, 0.8-1.2). The 1-year mortality rate among all patients was 26.2% (122/465), with a mortality rate of 18.1% (52/288) for stage III patients and 39.5% (70/177) for stage IV patients. Multivariate Cox proportional hazards regression analysis showed a significant negative association between CCR and 1-year all-cause mortality in breast cancer patients (adjusted HR = 0.68, 95% CI: 0.63-0.74, Conclusion: The serum creatinine-cystatin C ratio is an independent predictor of 1-year mortality risk in advanced breast cancer, with higher levels associated with significantly reduced mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.